Welby Corporation

After graduating from the School of Medicine, Chiba University, worked in clinical practice as a physician.

After graduating from the School of Medicine, Chiba University, worked in clinical practice for a total of 11 years, specializing primarily in diabetes and clinical nutrition at Kohnodai Hospital, National Center of Neurology and Psychiatry (now Kohnodai Hospital, National Center for Global Health and Medicine), and Tochigi Saiseikai Utsunomiya Hospital.

Worked at Shinkin Central Bank in corporate credit assessment and financial engineering, corporate planning, and corporate sales to entities including public organizations and financial institutions.

After graduating from Nagaoka University of Technology, joined Mochida Pharmaceutical Co., Ltd. and worked as a medical representative responsible for hospitals.

After graduating from Nagaoka University of Technology, joined Mochida Pharmaceutical Co., Ltd. and worked as a medical representative responsible for hospitals.

After graduating from the Faculty of Law at Doshisha University, joined Sumitomo Corporation. Worked on a joint venture to bring a U.S. high-tech startup into Japan, handling business development, product development, and promotion for the Japanese market for Silicon Valley companies, primarily in the cable TV industry. After leaving the company, enrolled in the MBA program at the University of Virginia in 2005 and earned an MBA. From 2007, worked on business strategy and organizational reform at Rakuten, Inc. Left the company in 2008 and helped launch an online community for healthcare professionals.

Joined CTC Laboratory Systems Corporation (now ITOCHU Techno-Solutions Corporation). After working in sales for proposals of comprehensive solutions and system integration projects using advanced IT across the pharmaceutical industry, particularly in drug discovery research and development, served as General Manager of Sales and General Manager of Marketing.

Worked at Rakuten, Inc. in the Corporate Strategy Division, as the head of several businesses, and in venture investment.

Founded Welby in 2011 and became its co-representative.

Founded Welby and became its co-representative.

Worked for many years at Torii Pharmaceutical Co., Ltd. in research and development, providing drug information, and customer consultation. From 2013, as a director and responsible marketing authorization holder, oversaw quality and safety assurance for the company's products.

At Frontier Turnaround, Inc. (now Frontier Management Inc.), served as a dispatched director and CXO at multiple publicly listed and fund-backed companies, including CRO and other industrial materials companies, working on corporate value enhancement and restructuring, mergers and acquisitions, and partnerships.

Joined Daiichi Sankyo Company, Limited and worked on digital transformation initiatives inside and outside the company as an innovation and digital transformation lead and digital health technology advisor.

Established a management consulting firm and became its Representative Director (current); became Representative Director of a university-originated deep-tech venture in the materials field (current).

Naoya Matsumoto appointed as director.

Taro Ishibashi appointed as director.

Joined FRONTEO, Inc., led the launch of its AI drug discovery business as Head of the Life Science AI Business Division, and advanced its medical digital transformation and AI medical device businesses.

Joined Welby in October 2023.

Joined Welby.

Drawing on experience providing information to patients and healthcare professionals, became a director in March 2024.

Yuko Karaya appointed as director.

Appointed as director in March 2026.

Kenichiro Shimizu appointed as director.

Masashi Hirano appointed as director.